- Almac Group has announced a $48 million investment in eClinical technologies, including the launch of its interoperable platform, Almac Trial Coordinator™.
- The investment also includes enhancements to its eClinical ecosystem and the creation of over 100 advanced technology roles globally.
Almac Group has unveiled a $48 million investment in eClinical technologies, designed to address key challenges facing sponsors, CROs, and clinical sites. Central to the investment is the launch of Almac Trial Coordinator™, a first-in-class interoperable clinical trial technology platform.
The platform unifies operational processes, clinical data, and systems into a single protocol, addressing the industry’s fragmentation challenge. Its open APIs, standards-based exports, and role-specific interfaces allow sponsors and sites to manage trials with full visibility, faster protocol amendments, and reduced operational risk.
“This investment underscores our commitment to delivering flexible, scalable solutions that empower sponsors and sites to run complex trials with confidence and efficiency. Almac Trial Coordinator™ is a transformative solution with a unique focus on streamlining the site’s ability to navigate today’s eClinical ecosystem with confidence and ease – addressing a critical industry need that does not get enough attention.”
Valarie Higgins, President & Managing Director at Almac Clinical Technologies.
The platform also features multilingual support, localisation, reusable libraries of standardised study templates, and robust data provenance. According to Kees van Ooik, Vice President of eClinical Solutions, the initiative enhances interoperability, improves user experience, and strengthens Almac’s ability to meet the evolving needs of global clinical trials.
By integrating these innovations into its eClinical ecosystem, Almac Group aims to simplify trial complexity, expand the number of sites able to conduct modern clinical studies, and improve patient engagement and trial quality across its global operations.
